AI Model Links Tumor Mutations to Treatment Response (today.ucsd.edu)

Researchers at UC San Diego have introduced an innovative AI model named MutationProjector, designed to enhance the prediction of cancer treatment responses by analyzing a tumor's entire genetic profile. Trained on genomic data from over 30,000 tumors across ten different solid cancer types, this model is a significant advancement over current approaches, which typically focus on a limited number of known biomarkers. By interpreting the complex interplay of multiple mutations, MutationProjector can not only predict how tumors might respond to immunotherapy and chemotherapy but also identify both established and novel biomarkers linked to treatment outcomes. The significance of this model lies in its potential to revolutionize precision oncology by making genetic testing more clinically actionable. Traditional treatment stratification often fails to match patients with effective therapies, primarily due to the reliance on a narrow set of biomarkers—currently, only 8% of cases lead to FDA-approved treatment matches. MutationProjector addresses this challenge by offering a broader understanding of molecular pathways altered by tumor mutations, thereby enhancing the interpretability of genetic data. As the researchers look to expand this model's application to more cancer types and integrate additional clinical data, it holds promise for significantly improving the efficacy of personalized cancer treatments.